Concepts (268)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 11 | 2024 | 68 | 3.870 |
Why?
|
| Liver Transplantation | 14 | 2024 | 53 | 3.220 |
Why?
|
| Glomerular Filtration Rate | 12 | 2024 | 61 | 2.090 |
Why?
|
| Kidney Failure, Chronic | 6 | 2020 | 25 | 1.840 |
Why?
|
| Kidney Diseases | 7 | 2023 | 38 | 1.750 |
Why?
|
| Humans | 70 | 2024 | 14077 | 1.650 |
Why?
|
| Living Donors | 7 | 2024 | 20 | 1.530 |
Why?
|
| Tissue and Organ Procurement | 7 | 2024 | 14 | 1.450 |
Why?
|
| South Africa | 46 | 2024 | 7312 | 1.410 |
Why?
|
| Kidney | 6 | 2024 | 46 | 1.400 |
Why?
|
| HIV Infections | 15 | 2024 | 4946 | 1.210 |
Why?
|
| Colorectal Neoplasms | 6 | 2022 | 47 | 1.080 |
Why?
|
| Renal Dialysis | 3 | 2015 | 25 | 1.040 |
Why?
|
| Male | 32 | 2024 | 6489 | 1.000 |
Why?
|
| Osteoporosis | 2 | 2023 | 14 | 0.990 |
Why?
|
| Sarcopenia | 2 | 2021 | 7 | 0.970 |
Why?
|
| Communication | 2 | 2022 | 56 | 0.960 |
Why?
|
| Female | 36 | 2024 | 8751 | 0.950 |
Why?
|
| Tacrolimus | 1 | 2024 | 5 | 0.930 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2024 | 11 | 0.920 |
Why?
|
| Immunosuppressive Agents | 1 | 2024 | 20 | 0.920 |
Why?
|
| Renal Replacement Therapy | 4 | 2020 | 6 | 0.900 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2024 | 190 | 0.890 |
Why?
|
| Creatinine | 8 | 2024 | 51 | 0.880 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2023 | 25 | 0.870 |
Why?
|
| Pharmacogenetics | 1 | 2023 | 27 | 0.870 |
Why?
|
| Genotype | 2 | 2024 | 430 | 0.860 |
Why?
|
| Social Media | 1 | 2022 | 6 | 0.780 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2021 | 12 | 0.770 |
Why?
|
| AIDS-Associated Nephropathy | 3 | 2013 | 6 | 0.760 |
Why?
|
| Cross Infection | 1 | 2021 | 49 | 0.760 |
Why?
|
| Adult | 25 | 2024 | 5664 | 0.750 |
Why?
|
| Middle Aged | 18 | 2024 | 3425 | 0.740 |
Why?
|
| Social Perception | 2 | 2017 | 7 | 0.720 |
Why?
|
| Pandemics | 1 | 2022 | 280 | 0.710 |
Why?
|
| Terminal Care | 2 | 2017 | 34 | 0.700 |
Why?
|
| Nephrology | 2 | 2020 | 2 | 0.680 |
Why?
|
| Graft Survival | 7 | 2024 | 40 | 0.680 |
Why?
|
| Hepatectomy | 1 | 2019 | 2 | 0.670 |
Why?
|
| Cystatin C | 3 | 2024 | 9 | 0.650 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2017 | 247 | 0.640 |
Why?
|
| Aged | 11 | 2024 | 1650 | 0.620 |
Why?
|
| Kidney Transplantation | 5 | 2021 | 42 | 0.590 |
Why?
|
| Retrospective Studies | 11 | 2024 | 767 | 0.580 |
Why?
|
| Hypertension | 4 | 2024 | 397 | 0.560 |
Why?
|
| HIV Seropositivity | 3 | 2019 | 263 | 0.560 |
Why?
|
| Uganda | 5 | 2024 | 194 | 0.550 |
Why?
|
| Adolescent | 13 | 2024 | 2858 | 0.550 |
Why?
|
| Child | 13 | 2024 | 2180 | 0.530 |
Why?
|
| Child, Preschool | 11 | 2024 | 1675 | 0.510 |
Why?
|
| Peritoneal Dialysis | 1 | 2015 | 8 | 0.500 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 48 | 0.490 |
Why?
|
| Health Care Rationing | 1 | 2014 | 16 | 0.470 |
Why?
|
| Malawi | 3 | 2024 | 86 | 0.470 |
Why?
|
| Risk Factors | 9 | 2023 | 1431 | 0.450 |
Why?
|
| Infant | 10 | 2024 | 2145 | 0.430 |
Why?
|
| Young Adult | 9 | 2024 | 2357 | 0.420 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2013 | 468 | 0.400 |
Why?
|
| Urinalysis | 2 | 2022 | 15 | 0.390 |
Why?
|
| Prevalence | 6 | 2023 | 1149 | 0.370 |
Why?
|
| Blood Pressure | 3 | 2024 | 312 | 0.370 |
Why?
|
| Private Sector | 3 | 2022 | 44 | 0.350 |
Why?
|
| Anti-Retroviral Agents | 2 | 2019 | 542 | 0.350 |
Why?
|
| Prospective Studies | 5 | 2022 | 1131 | 0.350 |
Why?
|
| Cohort Studies | 5 | 2022 | 939 | 0.340 |
Why?
|
| Africa South of the Sahara | 6 | 2023 | 328 | 0.340 |
Why?
|
| Postoperative Complications | 4 | 2024 | 32 | 0.330 |
Why?
|
| Renal Insufficiency | 1 | 2009 | 7 | 0.320 |
Why?
|
| Survival Rate | 4 | 2024 | 96 | 0.320 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 230 | 0.320 |
Why?
|
| Acidosis, Lactic | 1 | 2008 | 5 | 0.320 |
Why?
|
| Mass Screening | 2 | 2020 | 242 | 0.310 |
Why?
|
| Lactic Acid | 1 | 2008 | 33 | 0.310 |
Why?
|
| Genome-Wide Association Study | 3 | 2023 | 100 | 0.300 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 123 | 0.300 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 265 | 0.300 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2020 | 103 | 0.290 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 367 | 0.290 |
Why?
|
| Donor Selection | 3 | 2020 | 7 | 0.290 |
Why?
|
| Cross-Sectional Studies | 5 | 2023 | 1377 | 0.280 |
Why?
|
| Treatment Outcome | 6 | 2021 | 867 | 0.280 |
Why?
|
| Tissue Donors | 3 | 2024 | 17 | 0.260 |
Why?
|
| Rural Population | 2 | 2020 | 624 | 0.260 |
Why?
|
| Liver | 2 | 2023 | 74 | 0.260 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 449 | 0.260 |
Why?
|
| Comorbidity | 2 | 2020 | 184 | 0.240 |
Why?
|
| Albuminuria | 2 | 2023 | 20 | 0.240 |
Why?
|
| HIV-1 | 1 | 2013 | 1239 | 0.240 |
Why?
|
| Blood Group Incompatibility | 1 | 2024 | 3 | 0.230 |
Why?
|
| ABO Blood-Group System | 1 | 2024 | 5 | 0.230 |
Why?
|
| Waiting Lists | 1 | 2024 | 8 | 0.230 |
Why?
|
| Biliary Atresia | 2 | 2024 | 6 | 0.230 |
Why?
|
| Metabolic Clearance Rate | 1 | 2023 | 11 | 0.220 |
Why?
|
| United States | 1 | 2024 | 129 | 0.220 |
Why?
|
| Weight Gain | 1 | 2024 | 73 | 0.220 |
Why?
|
| Drug Discovery | 1 | 2023 | 22 | 0.220 |
Why?
|
| Iohexol | 2 | 2021 | 7 | 0.220 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2023 | 11 | 0.220 |
Why?
|
| Tenofovir | 1 | 2024 | 158 | 0.220 |
Why?
|
| Quality Indicators, Health Care | 2 | 2020 | 14 | 0.220 |
Why?
|
| Epidemics | 1 | 2024 | 64 | 0.210 |
Why?
|
| Beneficence | 1 | 2022 | 1 | 0.210 |
Why?
|
| Personal Autonomy | 1 | 2022 | 5 | 0.210 |
Why?
|
| Developing Countries | 2 | 2023 | 385 | 0.210 |
Why?
|
| Alleles | 2 | 2021 | 134 | 0.210 |
Why?
|
| Lipids | 1 | 2023 | 81 | 0.210 |
Why?
|
| Sodium, Dietary | 1 | 2022 | 10 | 0.210 |
Why?
|
| Dyslipidemias | 1 | 2023 | 47 | 0.200 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 163 | 0.200 |
Why?
|
| Decontamination | 1 | 2021 | 1 | 0.200 |
Why?
|
| Ultraviolet Rays | 1 | 2021 | 7 | 0.200 |
Why?
|
| Hand Strength | 1 | 2021 | 7 | 0.200 |
Why?
|
| Disinfection | 1 | 2021 | 6 | 0.200 |
Why?
|
| Carbapenems | 1 | 2021 | 17 | 0.200 |
Why?
|
| Absorptiometry, Photon | 1 | 2021 | 83 | 0.190 |
Why?
|
| HIV | 2 | 2021 | 380 | 0.190 |
Why?
|
| Hospitals | 1 | 2021 | 102 | 0.190 |
Why?
|
| Machine Learning | 1 | 2021 | 19 | 0.190 |
Why?
|
| General Surgery | 1 | 2021 | 8 | 0.190 |
Why?
|
| Bone Density | 1 | 2021 | 103 | 0.180 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 41 | 0.180 |
Why?
|
| Colonic Polyps | 1 | 2020 | 1 | 0.180 |
Why?
|
| Colonoscopy | 1 | 2020 | 1 | 0.180 |
Why?
|
| Adenoma | 1 | 2020 | 4 | 0.180 |
Why?
|
| Liver Failure, Acute | 1 | 2020 | 3 | 0.180 |
Why?
|
| Body Composition | 1 | 2021 | 150 | 0.180 |
Why?
|
| Point-of-Care Testing | 1 | 2021 | 68 | 0.180 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 57 | 0.170 |
Why?
|
| Nephrotic Syndrome | 1 | 2019 | 5 | 0.170 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2019 | 5 | 0.170 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 5 | 0.170 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 59 | 0.170 |
Why?
|
| Amino Acid Substitution | 1 | 2019 | 35 | 0.170 |
Why?
|
| Operative Time | 1 | 2019 | 4 | 0.170 |
Why?
|
| Quality Improvement | 1 | 2020 | 32 | 0.170 |
Why?
|
| Organ Transplantation | 1 | 2019 | 2 | 0.170 |
Why?
|
| Health Status Disparities | 1 | 2019 | 34 | 0.170 |
Why?
|
| Membrane Proteins | 1 | 2019 | 34 | 0.170 |
Why?
|
| Length of Stay | 1 | 2019 | 43 | 0.170 |
Why?
|
| Early Diagnosis | 3 | 2023 | 80 | 0.160 |
Why?
|
| Liver Diseases | 1 | 2019 | 18 | 0.160 |
Why?
|
| Models, Theoretical | 1 | 2019 | 78 | 0.160 |
Why?
|
| Liver Failure | 1 | 2018 | 5 | 0.160 |
Why?
|
| Sepsis | 1 | 2020 | 101 | 0.160 |
Why?
|
| United Kingdom | 3 | 2023 | 32 | 0.160 |
Why?
|
| Chemoprevention | 1 | 2018 | 33 | 0.160 |
Why?
|
| Mutation | 1 | 2019 | 299 | 0.150 |
Why?
|
| Chronic Disease | 2 | 2009 | 100 | 0.150 |
Why?
|
| Time Factors | 2 | 2019 | 503 | 0.150 |
Why?
|
| Urban Population | 1 | 2019 | 246 | 0.150 |
Why?
|
| Glomerulonephritis | 2 | 2007 | 7 | 0.150 |
Why?
|
| Nursing Staff, Hospital | 1 | 2017 | 8 | 0.140 |
Why?
|
| Mothers | 1 | 2019 | 190 | 0.140 |
Why?
|
| Policy Making | 1 | 2017 | 30 | 0.140 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 235 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2015 | 89 | 0.120 |
Why?
|
| Morbidity | 1 | 2015 | 37 | 0.120 |
Why?
|
| Attitude of Health Personnel | 2 | 2017 | 102 | 0.110 |
Why?
|
| Public Sector | 1 | 2014 | 82 | 0.110 |
Why?
|
| Biopsy | 1 | 2013 | 37 | 0.110 |
Why?
|
| Prognosis | 1 | 2013 | 197 | 0.100 |
Why?
|
| Bayes Theorem | 2 | 2023 | 77 | 0.100 |
Why?
|
| Infant, Newborn | 3 | 2020 | 1410 | 0.090 |
Why?
|
| Patient Selection | 2 | 2020 | 40 | 0.080 |
Why?
|
| Obesity | 2 | 2024 | 356 | 0.080 |
Why?
|
| Hematuria | 1 | 2009 | 3 | 0.080 |
Why?
|
| Leukocytosis | 1 | 2009 | 3 | 0.080 |
Why?
|
| Proteinuria | 1 | 2009 | 14 | 0.080 |
Why?
|
| Reference Values | 1 | 2009 | 64 | 0.080 |
Why?
|
| Urinary Tract Infections | 1 | 2009 | 12 | 0.080 |
Why?
|
| Outpatients | 1 | 2009 | 36 | 0.080 |
Why?
|
| Ambulatory Care Facilities | 1 | 2009 | 125 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2008 | 15 | 0.070 |
Why?
|
| Kidney Glomerulus | 1 | 2007 | 5 | 0.070 |
Why?
|
| Antigen-Antibody Complex | 1 | 2007 | 11 | 0.070 |
Why?
|
| Virus Diseases | 1 | 2007 | 55 | 0.070 |
Why?
|
| Cyclosporine | 1 | 2006 | 4 | 0.070 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2006 | 28 | 0.060 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2006 | 21 | 0.060 |
Why?
|
| Streptococcal Infections | 1 | 2007 | 179 | 0.060 |
Why?
|
| Alanine | 1 | 2024 | 29 | 0.060 |
Why?
|
| End Stage Liver Disease | 1 | 2024 | 5 | 0.060 |
Why?
|
| Graft Rejection | 1 | 2024 | 14 | 0.060 |
Why?
|
| Oxazines | 1 | 2024 | 71 | 0.060 |
Why?
|
| Piperazines | 1 | 2024 | 73 | 0.060 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2024 | 76 | 0.060 |
Why?
|
| Pyridones | 1 | 2024 | 87 | 0.060 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2023 | 3 | 0.050 |
Why?
|
| Random Allocation | 1 | 2023 | 23 | 0.050 |
Why?
|
| Cholesterol, HDL | 1 | 2023 | 32 | 0.050 |
Why?
|
| Triglycerides | 1 | 2023 | 40 | 0.050 |
Why?
|
| Cholesterol | 1 | 2023 | 38 | 0.050 |
Why?
|
| Urine Specimen Collection | 1 | 2022 | 6 | 0.050 |
Why?
|
| Potassium | 1 | 2022 | 25 | 0.050 |
Why?
|
| Sodium | 1 | 2022 | 26 | 0.050 |
Why?
|
| Multimorbidity | 1 | 2023 | 42 | 0.050 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2022 | 23 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 96 | 0.050 |
Why?
|
| Sex Factors | 1 | 2023 | 224 | 0.050 |
Why?
|
| Genomics | 1 | 2022 | 106 | 0.050 |
Why?
|
| Histocompatibility Testing | 1 | 2021 | 26 | 0.050 |
Why?
|
| Oligonucleotides | 1 | 2021 | 19 | 0.050 |
Why?
|
| Cholesterol, LDL | 1 | 2023 | 137 | 0.050 |
Why?
|
| Supervised Machine Learning | 1 | 2021 | 4 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2021 | 14 | 0.050 |
Why?
|
| Life Style | 1 | 2022 | 80 | 0.050 |
Why?
|
| ErbB Receptors | 1 | 2021 | 14 | 0.050 |
Why?
|
| Hospitals, Private | 1 | 2021 | 8 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2021 | 50 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 21 | 0.050 |
Why?
|
| Catastrophic Illness | 1 | 2020 | 2 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 11 | 0.050 |
Why?
|
| Early Medical Intervention | 1 | 2020 | 7 | 0.050 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2020 | 17 | 0.050 |
Why?
|
| Benchmarking | 1 | 2020 | 10 | 0.050 |
Why?
|
| Medical Audit | 1 | 2020 | 26 | 0.050 |
Why?
|
| Reoperation | 1 | 2020 | 8 | 0.050 |
Why?
|
| Education | 1 | 2020 | 22 | 0.050 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 9 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 13 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 39 | 0.040 |
Why?
|
| Health Resources | 1 | 2021 | 65 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 48 | 0.040 |
Why?
|
| Cultural Characteristics | 1 | 2020 | 15 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2020 | 54 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 37 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2020 | 13 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 210 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2021 | 88 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 31 | 0.040 |
Why?
|
| Health Expenditures | 1 | 2020 | 34 | 0.040 |
Why?
|
| Violence | 1 | 2020 | 68 | 0.040 |
Why?
|
| Steroids | 1 | 2019 | 14 | 0.040 |
Why?
|
| Apolipoprotein L1 | 1 | 2019 | 6 | 0.040 |
Why?
|
| Pedigree | 1 | 2019 | 30 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 532 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2019 | 35 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2020 | 131 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2020 | 43 | 0.040 |
Why?
|
| Poverty | 1 | 2020 | 149 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 29 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2019 | 55 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2019 | 27 | 0.040 |
Why?
|
| Haplotypes | 1 | 2019 | 119 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2021 | 228 | 0.040 |
Why?
|
| Research Design | 1 | 2020 | 123 | 0.040 |
Why?
|
| Critical Illness | 1 | 2019 | 42 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 409 | 0.040 |
Why?
|
| Birth Weight | 1 | 2019 | 78 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2020 | 294 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2019 | 217 | 0.040 |
Why?
|
| Logistic Models | 1 | 2019 | 252 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2018 | 165 | 0.040 |
Why?
|
| Incidence | 1 | 2020 | 655 | 0.040 |
Why?
|
| Professional-Family Relations | 1 | 2017 | 4 | 0.040 |
Why?
|
| Nurse's Role | 1 | 2017 | 5 | 0.040 |
Why?
|
| Communication Barriers | 1 | 2017 | 10 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2017 | 30 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2018 | 303 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2017 | 29 | 0.040 |
Why?
|
| HIV Antibodies | 1 | 2018 | 243 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 2024 | 1275 | 0.030 |
Why?
|
| Viral Load | 1 | 2018 | 808 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2010 | 464 | 0.020 |
Why?
|
| Contraindications | 1 | 2008 | 5 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2007 | 5 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2010 | 235 | 0.020 |
Why?
|
| Animals | 1 | 2007 | 1063 | 0.010 |
Why?
|